Results 191 to 200 of about 12,403 (234)

Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis

Arthritis & Rheumatology
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing, inflammatory disease. Management of EGPA predominantly relies on oral corticosteroids (OCS), which are associated with many adverse effects.
Michael E. Wechsler, J. Silver, G. Wolff, Robert G. Price, R. Verghis, P. F. Weller, P. Merkel, P. Khoury   +7 more
semanticscholar   +1 more source

Highlights from the plenary session: eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome.

Rheumatology
Hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) both present with hypereosinophilia and organ damage induced by eosinophils. EGPA is also characterized by vasculitis and is associated with ANCA.
J. Holle, Augusto Vaglio
semanticscholar   +1 more source

Therapeutic Advances in Eosinophilic Granulomatosis with Polyangiitis.

Rheumatic Disease Clinics of North America, 2023
Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic vasculitis that affects a variety of organ systems. Historically, glucocorticoids and a variety of other immunosuppressants were used to abrogate the inflammation and tissue injury ...
J. L. Bloom, C. Langford, M. Wechsler
semanticscholar   +1 more source

Cluster Analysis to Explore Clinical Subphenotypes of Eosinophilic Granulomatosis With Polyangiitis

Journal of Rheumatology, 2023
Objective Previous studies suggested that distinct phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome) could be determined by the presence or absence of antineutrophil cytoplasmic antibodies (ANCA),
Emma Rubenstein, C. Maldini, Augusto Vaglio, F. Bello, J. Bremer, F. Moosig, P. Bottero, Alberto Pesci, R. Sinico, J. Grosskreutz, Claudia Feder, D. Saadoun, Giorgio Trivioli, F. Maritati, B. Rewerska, W. Szczeklik, P. Fraticelli, Giuseppe Guida, G. Gregorini, G. Moroncini, B. Hellmich, J. Zwerina, Matthieu Resche-Rigon, G. Emmi, T. Neumann, A. Mahr   +25 more
semanticscholar   +1 more source

Long-term Effectiveness of Benralizumab in Eosinophilic Granulomatosis with Polyangiitis.

Journal of Allergy and Clinical Immunology: In Practice
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a multi-systemic disease characterised by eosinophilic tissue inflammation. Benralizumab, an anti-IL-5-receptor monoclonal antibody, induces rapid depletion of eosinophils; its longer ...
A. Nanzer, Anne-Catherine Maynard-Paquette, V. Alam, L. Green, L. Thomson, J. Lam, M. Fernandes, C. Roxas, G. D'ancona, A. Hearn, Jessica Gates, Sangita Agarwal, Brian D. Kent, Michelle Fernando, David D'Cruz, Claire Hopkins, Tevfik F. Ismail, J. Dhariwal, David J. Jackson   +18 more
semanticscholar   +1 more source

Cardiac involvement in eosinophilic granulomatosis with polyangiitis: acute eosinophilic myocarditis and chronic inflammatory cardiomyopathy.

Rheumatology
OBJECTIVES Currently, cardiac involvement is used to describe all eosinophilic granulomatosis with polyangiitis (EGPA) cardiac problems. However, heterogeneity exists among them.
Xiaohang Liu, Yangzhong Zhou, Jing Li, Tianchen Guo, Zhu Lv, Dingding Zhang, Xiaojin Feng, Jingdai Zhang, Ligang Fang, X. Tian, Xiaofeng Zeng, Wei Chen   +11 more
semanticscholar   +1 more source

Long-term efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: a propensity score matching analysis in the multicenter REVEAL cohort study

Frontiers in Immunology
Background Mepolizumab (MPZ) has demonstrated efficacy in clinical trials for eosinophilic granulomatosis with polyangiitis (EGPA); however, few studies compare the disease course between patients treated with MPZ (MPZ group) and those who were not ...
Mayu Shiomi, R. Watanabe, S. Matsuda, Takuya Kotani, Ayana Okazaki, Y. Masuda, Tsuneyasu Yoshida, Mikihito Shoji, R. Tsuge, K. Kadoba, R. Hiwa, W. Yamamoto, Akitoshi Takeda, Yoshiaki Itoh, M. Hashimoto   +14 more
semanticscholar   +1 more source

Red flags for clinical suspicion of eosinophilic granulomatosis with polyangiitis (EGPA).

European journal of internal medicine
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA), is a rare ANCA-associated systemic vasculitis. Its overlapping features with other vasculitic or eosinophilic diseases, and the wide and heterogeneous range of clinical manifestations ...
R. Solans Laqué, Í. Rúa-Figueroa, M. Blanco Aparicio, I. García Moguel, R. Blanco, F. Pérez Grimaldi, A. Noblejas Mozo, M. Labrador Horrillo, J. Álvaro-Gracia, C. Domingo Ribas, G. Espígol-Frigolé, F. Sánchez-Toril López, F. O. Ortiz Sanjuan, E. Arismendi, M. Cid   +14 more
semanticscholar   +1 more source

Efficacy and Safety of Reslizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA).

Annals of Allergy, Asthma & Immunology, 2021
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA), a rare vasculitis with significant morbidity, is characterized by asthma, eosinophilia, sinusitis, pulmonary infiltrates, neuropathy, +ANCA, and multi-organ vasculitis.
L. Manka, V. Guntur, J. Denson, Ryan M. Dunn, Yeshai Dollin, M. Strand, M. Wechsler   +6 more
semanticscholar   +1 more source

Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies

Current Rheumatology Reports, 2018
Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic disseminated vasculitis associated with extravascular granulomas in patients suffering from asthma and tissue eosinophilia. Current therapies to achieve remission and prevent relapse include glucocorticoids and immunosuppressants like cyclophosphamide.With the right treatment, clinical ...
Erika P, Navarro-Mendoza, Gabriel J, Tobón   +1 more
openaire   +2 more sources